Skip to main content
. Author manuscript; available in PMC: 2018 Apr 16.
Published in final edited form as: Br J Haematol. 2017 Mar 24;177(2):263–270. doi: 10.1111/bjh.14541

Fig 2.

Fig 2

Fig 2

(A) Overall survival by treatment

FND→R, sequential fludarabine, mitoxantrone, dexamethasone followed by rituximab; RFND, concurrent fludarabine, mitoxantrone, dexamethasone and rituximab.

(B) Overall survival by Follicular Lymphoma International Prognostic Index (FLIPI) score